MedPath

A Randomized Trial of Base-in Prism Reading Glasses Convergence Insufficiency in Children

Phase 3
Completed
Conditions
Convergence Insufficiency
Registration Number
NCT00347581
Lead Sponsor
Pennsylvania College of Optometry
Brief Summary

This study is designed to compare the use of special prism glasses to placebo treatment for children with symptomatic convergence insufficiency.

Detailed Description

The Base-in for Convergence Insufficiency Treatment Trial (BI-CITT) is a multi-center, placebo-controlled, masked, clinical trial designed to compare the benefits of base-in prism for patients with convergence insufficiency (CI).

The goals of this clinical trial are:

* To compare the effectiveness of Base-in prism and Placebo eyeglasses for the treatment of CI in children

* To study the long-term effect of these treatments for CI

* To identify factors that may be associated with successful treatment of CI with base-in prism

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
72
Inclusion Criteria
  • Age: 9 to <19 years.
  • Best corrected visual acuity of ≥20/25 in each eye at distance and near
  • Willingness to wear eyeglasses or contact lenses to correct refractive error, if necessary
  • Willingness to wear glasses for reading and other near work
  • Exophoria at near at least 4 greater than at far
  • Insufficient positive fusional convergence (fails Sheard's criterion)
  • Receded near point of convergence of  6 cm break
  • Random dot stereopsis appreciation using a 500 seconds of arc target.
  • CI Symptom Survey score  16
Exclusion Criteria
  • Amblyopia (> 2 line difference in best corrected visual acuity between the two eyes).
  • Constant strabismus
  • History of strabismus surgery.
  • Anisometropia  2D in any meridian between the eyes.
  • Prior refractive surgery.
  • Vertical heterophoria greater than 1 .
  • Systemic diseases known to affect accommodation, vergence and ocular motility such as: multiple sclerosis, Graves thyroid disease, myasthenia gravis, diabetes, Parkinson disease.
  • Any ocular or systemic medication known to affect accommodation or vergence (Anti-anxiety agents (Librium or Valium), Anti-arrhythmic agents (Cifenline or Cibenzoline), Anticholinergics (Motion sickness patch (scopolamine), Bladder spasmolytic drugs (Propiverine), Chloroquine, Phenothiazines (Compazine, Mellaril, or Thorazine), Tricyclic antidepressants (Elavil, Nortriptyline, or Tofranil)
  • Accommodative amplitude <5 D in either eye as measured by the Donder's push-up method.
  • Manifest or latent nystagmus.
  • Developmental disability, mental retardation, attention deficit hyperactivity disorder (ADHD), or learning disability diagnosis in children that in the investigator's discretion would interfere with treatment.
  • Household member or sibling already enrolled in the BI-CITT.
  • Any eye care professional, ophthalmic technician, ophthalmology or optometry resident or optometry student.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Symptom score on the Convergence Insufficiency Symptom Survey
Secondary Outcome Measures
NameTimeMethod
Positive fusional vergence at near
Near point of convergence

Trial Locations

Locations (10)

University of Alabama, Birmingham, College of Optometry

🇺🇸

Birmingham, Alabama, United States

The Ohio State University

🇺🇸

Columbus, Ohio, United States

Southern California College of Optometry

🇺🇸

Fullerton, California, United States

NOVA College of Optometry

🇺🇸

Ft. Lauderdale, Florida, United States

Bascom Palmer Eye Institute

🇺🇸

Miami, Florida, United States

Indiana University College of Optometry

🇺🇸

Bloomington, Indiana, United States

The Ohio State University, Optometry Coordinating Center

🇺🇸

Columbus, Ohio, United States

State University of New York, College of Optometry

🇺🇸

New York, New York, United States

Eye Institute, Pennsylvania College of Optometry

🇺🇸

Philadelphia, Pennsylvania, United States

University of Houston, College of Optometry

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath